Investigating the role of HIPK2 in pulmonary arterial hypertension
Official title: HIPK2 signaling in Pulmonary Arterial Hypertension
Funded at University of Pittsburgh at Pittsburgh · NIH-11096004 · Data updated 2026-11-12
This study is looking at how a protein called HIPK2 affects lung blood pressure in people with pulmonary arterial hypertension (PAH), with the hope of finding new ways to treat this condition and improve patients' health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project start | February 20, 2023 |
| Project end | January 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $358,824 |
| NIH project number | 5R01HL166932-03 |
| Project ID | NIH-11096004 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pulmonary arterial hypertension.
✕Less likely to help
Patients with other forms of pulmonary hypertension unrelated to the mechanisms being studied may not benefit from this research.
What this research studies
This research focuses on understanding how HIPK2, a protein involved in cell growth and survival, contributes to pulmonary arterial hypertension (PAH), a serious condition characterized by high blood pressure in the lungs. The study aims to explore the mechanisms by which HIPK2 influences the proliferation and survival of specific cells in the pulmonary arteries, which are crucial for the disease's progression. By examining the role of HIPK2 in these processes, the research seeks to identify new therapeutic targets that could lead to effective treatments for PAH. Patients may benefit from insights gained that could lead to innovative therapies aimed at reversing the harmful changes in their pulmonary arteries.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively reverse the progression of pulmonary arterial hypertension.
How similar studies have gone: While the specific role of HIPK2 in PAH has not been extensively studied, similar approaches targeting cell signaling pathways have shown promise in other conditions.
Where this research is happening
-
University of Pittsburgh at Pittsburgh
Pittsburgh, United States Active
Researchers
- Principal investigator: Kudryashova, Tatiana V — University of Pittsburgh at Pittsburgh
- Study coordinator: Kudryashova, Tatiana V
Related research
Other NIH-funded projects on the same topics.
-
Understanding how blood flow and pressure affect lungs in PAH
This grant studies how abnormal blood flow and pressure contribute to pulmonary arterial hypertension and how patient factors shape these effects, with the aim of guiding better therapies.
-
Asporin as a double-targeted therapy and biomarker for a serious artery disease
This project tests a protein called asporin as both a treatment and a biomarker for pulmonary arterial hypertension (PAH) to help people with this life-threatening condition.
-
Platelets and fibroblasts linked to energy use in a hard-to-treat blood vessel disease
A research team at the University of Pittsburgh is studying how platelet energy metabolism and fibroblast glutamine use interact in systemic sclerosis-related pulmonary arterial hypertension to improve diagnosis and treatment.
-
A biatrial dual‑lumen catheter to help the heart and lungs in pulmonary arterial hypertension
A new double‑lumen catheter is being developed to unload the right side of the heart and protect the lungs for people with pulmonary arterial hypertension.
-
Endothelial inflammation and Src kinase in early pulmonary arterial hypertension
Researchers are studying how inflammation in the lining of blood vessels and a protein called Src kinase contribute to early lung artery remodeling in people with mild PAH.
-
Cardiopulmonary chip model to study right heart disease from high blood pressure in the lungs
A tiny heart-lung chip is being developed to understand why the right side of the heart enlarges in people with pulmonary arterial hypertension and to test targeted treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.